We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

59 hedge funds and large institutions have $3.34M invested in Oncolytics Biotech in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 3 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 3

36% more capital invested

Capital invested by funds: $2.45M → $3.34M (+$887K)

1.06% more ownership

Funds ownership: 2.79% → 3.84% (+1.1%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

3% less funds holding

Funds holding: 61 → 59 (-2)

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
17
Reduced
3
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$712K
2
Marshall Wace
Marshall Wace
United Kingdom
+$594K
3
SFP
Sandbox Financial Partners
Maryland
+$398K
4
EFG
Everhart Financial Group
Ohio
+$137K
5
DA
Doliver Advisors
Texas
+$99.5K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$396K
2
IAIM
International Assets Investment Management
Florida
-$182K
3
Goldman Sachs
Goldman Sachs
New York
-$148K
4
CCM
Connective Capital Management
California
-$131K
5
VF
Virtu Financial
New York
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
51
Carson Wealth (CWM LLC)
Nebraska
$1.13K – – –
AF
52
Aviso Financial
Ontario, Canada
$1.11K +$1.25K +1,252 +2,408%
JP Morgan Chase
53
JP Morgan Chase
New York
$1.03K +$1.27K +1,277 New
TWC
54
TD Waterhouse Canada
Ontario, Canada
$562 +$261 +262 +66%
MCM
55
MAI Capital Management
Ohio
$447 – – –
SIS
56
Sound Income Strategies
Florida
$180 – – –
AIM
57
Axiom Investment Management
New York
$127 +$149 +150 New
DWM
58
Dogwood Wealth Management
Kansas
$124 – – –
EWM
59
Evolution Wealth Management
Florida
$89 +$104 +105 New
IAIM
60
International Assets Investment Management
Florida
– -$182K -208,150 Closed
Goldman Sachs
61
Goldman Sachs
New York
– -$148K -169,899 Closed
CCM
62
Connective Capital Management
California
– -$131K -150,340 Closed
VF
63
Virtu Financial
New York
– -$68K -77,883 Closed
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
– -$60K -68,311 Closed
BPWM
65
Badgley Phelps Wealth Managers
Washington
– -$35K -40,000 Closed
GSC
66
Ground Swell Capital
South Carolina
– -$30.1K -34,398 Closed
William Blair & Company
67
William Blair & Company
Illinois
– -$27.5K -31,467 Closed
BAM
68
Brave Asset Management
New Jersey
– -$21.9K -25,000 Closed
HA
69
Huntleigh Advisors
Missouri
– -$11.4K -13,000 Closed
VNA
70
Valley National Advisers
Pennsylvania
– -$6K -7,000 Closed
Bank of America
71
Bank of America
North Carolina
– -$874 -1,000 Closed
JFA
72
JNBA Financial Advisors
Minnesota
– -$184 -210 Closed
IPS
73
Investors Portfolio Services
Washington
– -$37 -42 Closed
WWM
74
Wolff Wiese Magana
California
– -$28 -31 Closed
Citigroup
75
Citigroup
New York
– -$1 -1 Closed
1 2
3

ONCY Hedge Fund Activity: Q1 2026 in Review

59 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2026, worth a combined $3.34M — up 36% from $2.45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ONCY and 15 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 17 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $712K. The largest seller was Morgan Stanley, cutting an estimated $396K.

  • 59 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2026, down from 61 in Q4 2025.
  • Funds reported $3.34M of Oncolytics Biotech stock for Q1 2026, up 36% quarter-over-quarter.
  • 15 funds opened new Oncolytics Biotech positions in Q1 2026 and 16 closed out, a net change of -1 holder.
  • The largest Oncolytics Biotech buyer in Q1 2026 was Renaissance Technologies, an estimated $712K added.
  • The largest Oncolytics Biotech seller in Q1 2026 was Morgan Stanley, an estimated $396K sold.

Based on aggregated 13F filings for Q1 2026.